Additional milestone payment and progress in prioritised projects Third quarter 2014, July – September · Net sales for July – September 2014 amounted to SEK 11 (7.8) million. · Earnings after tax for July – September 2014: SEK -10 (-15) million. · Earnings after tax per share for July – September before and after dilution: SEK -0.09 (-0.19). · Cash flow from current operations and investment activities for July – September 2014: SEK -3.9 (-19) million. Nine-month report 2014, January – September · Net sales for January – September 2014 amounted to SEK 45 (32) million. · Earnings after tax for January – September 2014: SEK -26 (-39) million. · Earnings after tax per share for January – September before and after dilution: SEK -0.26 (-0.51). · Liquid funds as of 30 September 2014: SEK 70 (40) million. Cash flow from current operations and investment activities for January – September 2014: SEK -52 (-80) million. Important events in the third quarter and after the reporting period · BioInvent announced in September that a milestone payment had been received from Bayer as the first patient was enrolled in a phase I clinical trial. Bayer now has three antibodies from BioInvent’s CoDeR® library in clinical phase I studies. Comments from the CEO ”In 2014 we have conducted a broad outreach to present BioInvent’s F.I.R.S.T.TM platform technology and our drug development projects to international pharma and biotech companies and to other key organisations. We have generated significant interest and are engaged in active discussions regarding our key projects. Our expertise and focus on immuno-oncology drive this interest. BioInvent has decided to give strategic priority to BI-1206. The rationale for this decision is the extensive preclinical data package, indicating broad application opportunities in oncology for BI-1206, which we have generated during the past few years. The results of the preclinical work will be published this coming winter / spring. In Q3, we have started production of BI-1206 and are conducting an important toxicology study with the objective to commence a phase I clinical trial in blood cancer (non-Hodgkin lymphoma) in 2015 ", said Michael Oredsson, CEO of BioInvent. Contact Any questions regarding this report will be answered by Michael Oredsson, CEO, phone.+46 (0)46 286 85 67, mobile +46 (0)707 18 89 30. The report is also available at www.bioinvent.com Information disclosed in this interim report is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 23 October, 2014. BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier and Xoma.
BioInvent Interim Report 1 January – 30 September 2014
Top 10 Most Recent News Articles
America's Group Adds Swansea to Its UK Auction Map
A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...
Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test
Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...
Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition
In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...
Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close
One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...
Continue Reading
Triple Crossing Tests a Tough Inland Marine Market
Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...
Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition
Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...
Continue Reading
Animal Parasite Market Growth Has a Resistance Catch
Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...
Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap
The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...
Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check
A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...
Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice
A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...
Continue ReadingTop 5 Most Recently Viewed Articles
Exciting Changes in Leadership Position at ibex Limited
Board of Directors' Transformation at ibex Limited ibex Limited, a prominent player in global business process outsourcing, has recently made significant changes to its Board of Directors. The company announced that Gerard Kleisterlee will retire from his position after the upcoming Annual General Meeting (AGM). A Fond Farewell to Gerard Kleisterlee Gerard has been an...
Continue Reading
Umicore's Shareholding Update: Impact and Insights
Investor Transparency Notification from Silchester International Investors LLP Transparency notification by Silchester International Investors LLP Umicore has recently received a significant transparency notification regarding shareholding changes from Silchester International Investors LLP. This notification falls under the legal obligations concerning major holdings as...
Continue Reading
Exploring the Future of Retail at Digital Retail Africa 2025
Event Overview of Digital Retail Africa 2025 The retail landscape is experiencing significant change, and Digital Retail Africa 2025 aims to prepare businesses for the rapidly evolving challenges and opportunities that lie ahead. This influential event, scheduled for January 30, 2025, at a premier venue, will gather top industry professionals, innovators, and...
Continue Reading
Understanding the Impact of Wegovy's Medicare Negotiation
Implications of Wegovy's Medicare Price Negotiation The recent announcement regarding Medicare's negotiations for prescription medications has sparked considerable interest, particularly with the inclusion of Novo Nordisk's (NYSE: NVO) groundbreaking weight-loss drug, Wegovy. This decision marks a significant moment for both healthcare providers and patients across the...
Continue Reading
Max Stock Ltd. Receives Resignation News from Deputy CEO
Max Stock Ltd. Announces Resignation of Deputy CEO Max Stock Limited (TASE: MAXO) has revealed that Mr. Nir Dagan, the Company’s Deputy CEO and Head of Finance, has decided to resign after nine impactful years of service. Mr. Dagan will remain in his position until the end of the calendar year. The Company appreciates Mr. Dagan’s extensive contribution over the years,...
Continue Reading